期刊文献+

利血平对耐药结核分枝杆菌临床株的作用 被引量:1

Effects of Reserpine on the Drug-Resistant Mycobacterium tuberculosis
下载PDF
导出
摘要 目的观察泵抑制剂(利血平)对耐药结核分枝杆菌临床分离株的作用。方法应用3组BacT.ALERT3D培养仪系统的培养基,分别命名为A、B、C组培养基。3组培养基均接种42株耐药结核分枝杆菌临床分离株,其中A、B组同时加入利福平1μg/mL;环丙沙星2μg/mL;利福平1μg/mL和环丙沙星2μg/mL;A、C组同时加入利血平20mg/L;C组未加入任何抗结核药物。结果在A组培养基中,耐利福平1μg/mL的14株菌株中有2株恢复对利福平的敏感性,12株仍然耐药;耐环丙沙星2μg/mL的6株菌株和耐利福平1μg/mL及环丙沙星2μg/mL的22株菌株全部恢复药物敏感性。在B组培养基中,42株耐药结核分枝杆菌临床分离株,药物耐药性无变化。在C组培养基中,42株耐药结核分枝杆菌临床分离株明显生长,说明利血平对所研究菌株无抑制作用。A组与B组培养基细菌的药物敏感性差异有统计学意义(P<0.01)。结论结核分枝杆菌存在耐药机制之一的外排系统;泵抑制剂之一利血平对耐药的结核分枝杆菌临床分离株有抑制其外排作用,使结核分枝杆菌恢复敏感性。 Objective To determine the antibacterial activities of an efflux pump inhibitor reserpine on the clinical isolates of drug-resistant Mycobacterium tuberculosis. Method BacT/ALERT3D was used in this study. 3 groups of culture plates (A, B, and C) were setup. 42 clinical isolates of M.tuberculosis were inoculated into group A, B, and C. Rifampicin (1 μg/mL), Ciprofloxacin (2 μg/mL), Rifampicin (1 μg/mL), and Ciprofloxacin (2 μg/mL) were added to both group A and group B. Reserpine (20 mg/L) was added to both A and C. Group C did not receive anti-tuberculosis drug. Result 2 of the 14 Rifampicin-resistant isolates were found to be sensitive to Rifampicin. All 6 Ciprofloxacin-resistant isolates and 22 both Ciprofloxacin- and Rifampicin-resistant isolates were found to be sensitive for the two drugs in A group. In group B, changes of drug sensitivity were not observed in all 42 isolates. In group C, the growth of all 42 isolates were similar, indicating that reserpine had no growth inhibitory effect on these isolates. A significant difference was found in the drug sensitivity between group A and group B (P 〈 0.01). Conclusion The efflux pump inhibitor reserpine can inhibit the drug efflux system of drug-resistant Mycobacterium tuberculosis and restores the drug sensitive of the bacteria to anti-tuberculosis drugs.
机构地区 广州市胸科医院
出处 《热带医学杂志》 CAS 2008年第2期128-129,共2页 Journal of Tropical Medicine
基金 广州市医药卫生科技项目(No.2006-YB-228)
关键词 结核 耐药性 利血平 tuberculosis drug resistance reserpine
  • 相关文献

参考文献9

  • 1刘军锋,贾克刚,刘运德.细菌耐药机制的研究进展[J].国际检验医学杂志,2006,27(11):1015-1017. 被引量:13
  • 2Pasca MR, Guglierame P, Arcesi F, et al. Rv2686c-Rv2687c- Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother, 2004,48(8) : 3175-3178.
  • 3Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related stains of Staphylococeus aureus [J]. Antimicrob Agents Chemother, 1997,41 (12) : 2733-2737.
  • 4Silva PE, Bigi F, Santangelo MP. Charaterization of P55,a multidrug eftlux pump is Mycobacterium bovis and Mycobacterium tuberculosis [J ]. Antimicrob Agents Chemother,2001,45 (3) :800-804.
  • 5吴龙章,蔡杏珊,潘美玉,曹务华,曹智忠,黄进晖.BacT/ALERT3D全自动培养仪在细菌鉴定和药敏试验的临床应用[J].中华检验医学杂志,2002,25(4):243-244. 被引量:25
  • 6宋诗铎.临床菌株耐药性产生和播散的机制[J].中国感染控制杂志,2004,3(2):97-99. 被引量:6
  • 7Brown MH, Panlsen IT, Slurray RA. The muhidrug efflux protein NorM is a prototype of a new family of transporters [ J ]. Mol Mierobiol, 1999,31 ( 1 ) : 394-395.
  • 8Piddock LJ, Williams KJ, Ricci V. Accumulation of rifampicin by Mycobacterium allrum , Mycobacterium smegmatis and Mycobacterium tuberculosis [J]. J Antimicrob Chemother, 2000,45(2) : 159-165.
  • 9黄海荣,马玙.结核分支杆菌耐利福平与rpoB基因[J].中华结核和呼吸杂志,2000,23(11):692-694. 被引量:12

二级参考文献24

  • 1结核病诊断细菌学检验规程[J].中国防痨杂志,1996,18(1):28-31. 被引量:799
  • 2吴龙章.BACTEC系统在结核菌快速培养中的应用[J].中华结核和呼吸杂志,1992,(4):245-245.
  • 3吴龙章.BACTEC系统检测分支杆菌若干影响因素的初步探讨[J].中华结核和呼吸杂志,1994,17:23-23.
  • 4[1]Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection[J]. Science, 2000, 288(5469): 1251-1254.
  • 5[2]Hooper D C. Emerging mechanisms of fluoroquinolone resistance[J]. Emerg Infect Dis, 2001, 7(2): 337-341.
  • 6[3]Lewis K. In search of natural substrates and inhibitors of MDR pumps[J]. J Mol Microbiol Biotechnol, 2001, 3(2): 247-254.
  • 7[4]Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci[J]. Antimicrob Agents Chemother, 2001, 45(7): 2154-2156.
  • 8Gingeras T R,Genome Res,1998年,8435页
  • 9Kapur V,J Clin Microbiol,1994年,32卷,1095页
  • 10Collis CM, Kim MJ, Partridge SR, et al. Characterization of the class 3 integron and the site-specific recombination system it determines. J Bacteriol. 2002, 184(11 ):3017-3026.

共引文献52

同被引文献18

  • 1巢国祥,焦新安,徐勤,钱晓勤,周丽萍,周晓辉,黄金林.8类食品单核细胞增生李斯特菌流行特征及耐药性状研究[J].中国卫生检验杂志,2005,15(5):519-521. 被引量:24
  • 2Godreuil S, Galimand M, Gerbaud G, et al. Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes [ J ] . Antimicrobial Agents and Chemotherapy, 2003, 47 ( 2 ) : 704-708.
  • 3yan H, Neogi SB, Mo Z, et al. Prevalence and characterization of antimicrobial resistance of foodborne Listeria monocytogenes isolates in Hebei province of Northern China, 2005-2007 [ J ] . International Journal of Food Microbiology, 2010, 144 ( 2 ) : 310-316.
  • 4Everett MJ, Jin ~F, Ricci V, et al. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals [ J ] . Antimicrobial Agents and Chemotherapy, 1996, 40 ( 10 ) : 2380-2386.
  • 5Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region[J]. Antimicrobial Agents and Chemothei'apy, 2001, 45 ( 8 ): 2378-2380.
  • 6Lampidis R, Kostrewa D, Hof H. Molecular characterization of the genes encoding DNA gyrase and topoisomerase IV of Listeria monocytogenes [ J ] . Journal of Antimicrobial Chemotherapy, 2002, 49 ( 6 ) : 917-924.
  • 7Ruiz J. Mechanisms of resistance to quinolones : target alterations, decreased accumulation and DNA gyrase protection [ J ] . Journal of Antimierobial Chemotherapy, 2003, 51 ( 5 ) : 1109-1117.
  • 8Hern~ndez A, S~nchez MB, Marfinez JL. Quinolone resistance : much more than predicted [ J ] . Frontiers in Microbiology, 2011, 2 : 22.
  • 9CLSI, 2012. Performance standards for antimicrobial susceptibility Testing CLSI Document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
  • 10Wang M, Tran JH, Jacoby GA, et al. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China[ J ]. Antimicrobial Agents and Chemotherapy, 2003, 47( 7 ): 2242-2248.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部